Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02871492 · ClinicalTrials.gov registry record · Phase 2
Trial on Efficacy and Safety of Pritelivir Ointment for Treatment of Labial Herpes
A Phase 2 study, sponsored by AiCuris Anti-infective Cures.
- Completed
- Registry status
- Phase 2
- Development phase
- 362
- Enrollment target
NCT02871492: Completed Phase 2 study, sponsored by AiCuris Anti-infective Cures.
NCT02871492 is a Phase 2 study that has completed, run by AiCuris Anti-infective Cures. The registered enrollment target is 362 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (172% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02871492, a Phase 2 study, has completed, sponsored by AiCuris Anti-infective Cures.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 362 participants
- Enrollment target
Study Summary
Randomized, double-blind, multi-center, three arm parallel group, comparative trial to assess pritelivir ointment safety and efficacy, ie, proportion of subjects with non-ulcerative lesions, in adult subjects with recurrent herpes labialis (RHL) in comparison with placebo or Zovirax® Cream. The start of treatment with trial medication will be initiated by the subject within one hour of noticing the first sign or symptom (eg, prodrome) of a recurrence of herpes labialis. Trial medication will be applied to the affected area 5 times daily for 4 days. After self-initiation of treatment with trial medication subjects will be assessed daily by the Investigator until complete healing for a maximum of 13 days. Subjects will document application of trial medication and the status of their lesion in a diary. There will also be blood sampling, ECG measurement and physical examination performed at the investigational site.
Primary Outcome
The Investigator assessed subjects for lesion stage at every visit as long as lesions were present from Visit 1 to the End of Trial Visit (Day 12± 1) as a maximum. Percentage of subjects with non-ulcerative lesions (i.e, scoring below 3) based on the Principal Investigators Assessment. Lesion stages were defined as follows: 1-Prodrome; 2a-Redness; 2b-Erythema-Redness; 3-Small Blister; 4-Ulcer; 5-Crust; 6-Drying up and healing; 0-Resolved
Interventions
- DRUG Pritelivir 5% w/w ointment
- DRUG Pritelivir ointment matching placebo
- DRUG Zovirax® cream
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 362 participants |
| Start Date | 2016-11-29 |
| Est. Completion | 2017-10-16 |
| Phase | Phase 2 |
What the finished NCT02871492 record still lists
NCT02871492 is an interventional study that assigns participants to a tested intervention. The registered 362 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (172% higher).
The record links to 0 conditions, and to 3 interventions - of which Pritelivir 5% w/w ointment is the first listed.
NCT02871492 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02871492 about?
NCT02871492 is a clinical study titled "Trial on Efficacy and Safety of Pritelivir Ointment for Treatment of Labial Herpes". Randomized, double-blind, multi-center, three arm parallel group, comparative trial to assess pritelivir ointment safety and efficacy, ie, proportion of subjects with non-ulcerative lesions, in adult subjects with recurrent herpes labialis (RHL) in comparison with placebo or Zovirax® Cream. The star...
What is the current status of trial NCT02871492?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 362 participants. The study started on 2016-11-29. Estimated completion is 2017-10-16.
What interventions are being tested in trial NCT02871492?
The interventions under investigation include: Pritelivir 5% w/w ointment (DRUG), Pritelivir ointment matching placebo (DRUG), Zovirax® cream (DRUG).
Who is sponsoring clinical trial NCT02871492?
This trial is sponsored by AiCuris Anti-infective Cures, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02871492's enrollment target sits among peer trials
362 122nd of 2000 higher than 1,878 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04988555 · 362 participants · Phase 1
A Study of DSP-5336 in Relapsed/Refractory AML/ ALL With or Without MLL Rearrangement or NPM1 Mutation
- NCT05536141 · 362 participants · Phase 1
A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors
- NCT06534983 · 362 participants · Phase 2
A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran With Nivolumab Versus Nivolumab Alone in Participants With High-risk Muscle-invasive Urothelial Carcinoma (MIUC)
- NCT06472245 · 363 participants · Phase 3
Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI